Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of AGX148 combined with PH-762 in subjects with advanced solid malignancies

Next Previous
Search
Trial Profile

Clinical trial of AGX148 combined with PH-762 in subjects with advanced solid malignancies

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AGX-148 (Primary) ; PH 762 TME (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 24 May 2023 According to a Phio Pharmaceuticals media release, the company in collaboration with Providence Cancer Institute, has completed the site initiation visit and can commence with patient accrual. The trial will be conducted at Providence Cancer Institute in Portland, Oregon, by Principal Investigator Brendan Curti, MD, Medical Oncologist and Robert W. Franz Endowed Chair for Clinical Research at the Earle A. Chiles Research Institute, a division of Providence.
    • 06 Jan 2023 Status changed from planning to not yet recruiting as per Phio Pharmaceuticals media release
    • 06 Jan 2023 According to Phio Pharmaceuticals media release, AgonOx, Inc. has received confirmation from the FDA that their planned Phase 1 clinical trial in patients with advanced solid tumors may proceed; The trial will be conducted at Providence under the leadership of Dr. Weinberg and Principal Investigator Brendan Curti, MD, Medical Oncologist and Robert W. Franz Endowed Chair for Clinical Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top